Certara

Guide

Pediatric Drug Development and Pharmacometrics: Key Questions Sponsors Must Answer

Download Certara’s expert guide on pharmacometrics and pediatric drug development. Learn how modeling, MIDD, and…

CertaraMarch 19, 2026

Press Coverage Video

Rethinking Trial Design With Bayesian Approaches

Learn how Bayesian approaches are transforming clinical trial design by enabling adaptive studies, data borrowing,…

CertaraMarch 19, 2026

Blog

The future of payer engagement in pharma: rethinking how value is communicated

A detailed analysis of strategies for payer engagement in pharma and how digital payer engagement…

CertaraMarch 19, 2026

Blog Knowledge Base

What is GLP (Good Laboratory Practice)?

Read this blog to understand GLP (Good Laboratory Practice) and associated QA audits, and proper…

CertaraMarch 18, 2026

Blog

ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug Development

With the release of the draft ICH M15 guidance, MIDD is no longer optional -…

CertaraMarch 18, 2026

Blog

Why You Should Participate in the Voluntary FDA Oncology Center of Excellence Assessment Aid Program

Learn how the FDA assessment aid streamlines oncology NDA/BLA reviews, what to include, and best…

CertaraMarch 17, 2026

Press Coverage Video

FDA Support Drives Shift Toward Bayesian Trial Design

Explore how Bayesian statistical methods are reshaping clinical trial design. Learn how FDA support, adaptive…

Danielle PillsburyMarch 13, 2026

Video

ADC Development & Differentiation Strategies | Quantitative Systems Pharmacology & MIDD

Learn how model-informed drug development (MIDD) and quantitative systems pharmacology (QSP) support antibody-drug conjugate (ADC)…

CertaraMarch 13, 2026

Press Coverage

Single Pivotal Trials Demand Stronger Data and Risk Strategies

As regulators increasingly accept single pivotal trials for drug approval, sponsors must strengthen data quality,…

CertaraMarch 13, 2026

Conference

Discovery & Development Europe 2026

CertaraMarch 13, 2026

Pediatric Drug Development and Pharmacometrics: Key Questions Sponsors Must Answer

Rethinking Trial Design With Bayesian Approaches

The future of payer engagement in pharma: rethinking how value is communicated

What is GLP (Good Laboratory Practice)?

ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug Development

Why You Should Participate in the Voluntary FDA Oncology Center of Excellence Assessment Aid Program

FDA Support Drives Shift Toward Bayesian Trial Design

ADC Development & Differentiation Strategies | Quantitative Systems Pharmacology & MIDD

Single Pivotal Trials Demand Stronger Data and Risk Strategies

Discovery & Development Europe 2026

Newsletter sign up

Quick links

Solutions

Contact